The role of complement in tumor growth.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Advances in Experimental Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-1-4614-5915-6_11PMID 24272362PMCID PMC4379038
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer

  2013cited by this paper
• Lancet Oncol 10

  2013cited by this paper
• Tumor Microenvironment and Myeloid-Derived Suppressor Cells

  2013cited by this paper
• Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting

  2012cited by this paper
• The immune contexture in human tumours: impact on clinical outcome

  2012cited by this paper
• Opposing Roles for Complement Component C5a in Tumor Progression and the Tumor Microenvironment

  2012cited by this paper
• Sublytic complement protects prostate cancer cells from tumour necrosis factor‐α‐induced cell death

  2012cited by this paper
• Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.

  2012cited by this paper
• Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids

  2012cited by this paper
• A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer.

  2012cited by this paper
• Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression

  2012influential reference
• Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy

  2012cited by this paper
• Altered expression of sialidases in human cancer.

  2012cited by this paper
• Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

  2012cited by this paper
• Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

  2012cited by this paper
• Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement.

  2012cited by this paper
• Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value

  2011cited by this paper
• Human complement factor H is a novel diagnostic marker for lung adenocarcinoma.

  2011cited by this paper
• Complement in Cancer and Cancer Immunotherapy

  2011influential reference
• Hallmarks of cancer: the next generation.

  2011influential reference
• A Perspective on Cancer Cell Metastasis

  2011cited by this paper
• Membrane attack by complement: the assembly and biology of terminal complement complexes

  2011cited by this paper
• Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice.

  2011cited by this paper
• Expression of tumour-specific antigens underlies cancer immunoediting

  2011cited by this paper
• Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo

  2010cited by this paper
• Complement: a key system for immune surveillance and homeostasis

  2010cited by this paper
• New insights into the molecular mechanisms of classical complement activation.

  2010cited by this paper
• Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer

  2010cited by this paper
• Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value

  2010cited by this paper
• Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis.

  2010cited by this paper
• Monoclonal antibodies: versatile platforms for cancer immunotherapy

  2010cited by this paper
• Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.

  2010cited by this paper
• Cancer and the Complement Cascade

  2010cited by this paper
• Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

  2010cited by this paper
• Immunity, inflammation, and cancer.

  2010cited by this paper
• The complement cascade as a mediator of tissue growth and regeneration

  2010cited by this paper
• Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.

  2009cited by this paper
• CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study.

  2009cited by this paper
• CD59 Silencing via Retrovirus-Mediated RNA Interference Enhanced Complement-Mediated Cell Damage in Ovary Cancer

  2009cited by this paper
• Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack

  2009influential reference
• Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development.

  2009influential reference
• The Regulation of Liver Cell Survival by Complement1

  2009cited by this paper
• C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy.

  2009cited by this paper
• Cooperation of decay-accelerating factor and membrane cofactor protein in regulating survival of human cervical cancer cells

  2009cited by this paper
• Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1

  2009cited by this paper
• Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation.

  2009cited by this paper
• C3a and C5a Are Chemotactic Factors for Human Mesenchymal Stem Cells, Which Cause Prolonged ERK1/2 Phosphorylation1

  2009cited by this paper
• Myeloid-derived suppressor cells as regulators of the immune system

  2009cited by this paper
• Modulation of the anti-tumor immune response by complement

  2008influential reference
• Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo

  2008cited by this paper
• The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).

  2008cited by this paper
• A role of macrophage complement receptor CRIg in immune clearance and inflammation.

  2008cited by this paper
• Properdin and complement activation: a fresh perspective.

  2008cited by this paper
• Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis1

  2008cited by this paper
• Biological activities of C1 inhibitor.

  2008cited by this paper
• Factor H family proteins and human diseases.

  2008cited by this paper
• The role of membrane complement regulatory proteins in cancer immunotherapy.

  2008cited by this paper
• Cancer-related inflammation

  2008cited by this paper
• Interaction between the coagulation and complement system.

  2008cited by this paper
• Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.

  2008cited by this paper
• C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a

  2007cited by this paper
• Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells.

  2007cited by this paper
• Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development

  2007cited by this paper
• Complement as effector system in cancer immunotherapy.

  2007cited by this paper
• Prion protein activates and fixes complement directly via the classical pathway: implications for the mechanism of scrapie agent propagation in lymphoid tissue.

  2007cited by this paper
• Down-Regulation of Human Complement Factor H Sensitizes Non-Small Cell Lung Cancer Cells to Complement Attack and Reduces In Vivo Tumor Growth1

  2007cited by this paper
• Alternative roles for CD59.

  2007cited by this paper
• Complement and coagulation: strangers or partners in crime?

  2007cited by this paper
• Increased surveillance of cells in mitosis by human NK cells suggests a novel strategy for limiting tumor growth and viral replication.

  2007cited by this paper
• Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis

  2007cited by this paper
• Macrophage complement receptors and pathogen clearance

  2007cited by this paper
• Anaphylatoxins: their role in bacterial infection and inflammation.

  2007cited by this paper
• Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10

  2007cited by this paper
• Tumour metabolomics in animal models of human cancer.

  2007cited by this paper
• Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins.

  2007cited by this paper
• Structural and Functional Characterization of a Novel T Cell Receptor Co-regulatory Protein Complex, CD97-CD55*

  2007cited by this paper
• Live Cell Imaging of Outward and Inward Vesiculation Induced by the Complement C5b-9 Complex*

  2007cited by this paper
• Translational Mini‐Review Series on Complement Factor H: Genetics and disease associations of human complement factor H

  2007cited by this paper
• Mannose binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo

  2006cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Tumor-driven evolution of immunosuppressive networks during malignant progression.

  2006cited by this paper
• Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2.

  2006cited by this paper
• Antibody targeted drugs as cancer therapeutics

  2006influential reference
• Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice.

  2006cited by this paper
• Faculty Opinions recommendation of CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens.

  2006cited by this paper
• Activation of the Lectin Pathway by Natural IgM in a Model of Ischemia/Reperfusion Injury1

  2006cited by this paper
• Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism.

  2006cited by this paper
• Distinct role of macrophages in different tumor microenvironments.

  2006cited by this paper
• Evidence That Complement Protein C1q Interacts with C-Reactive Protein through Its Globular Head Region1

  2006cited by this paper
• Generation of C5a in the absence of C3: a new complement activation pathway

  2006cited by this paper
• Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction

  2006cited by this paper
• Blockade of bulky lymphoma‐associated CD55 expression by RNA interference overcomes resistance to complement‐dependent cytotoxicity with rituximab

  2006cited by this paper
• Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.

  2006cited by this paper
• Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients

  2006cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• Cellular immunity and complement levels in hosts with brain tumours

  2005cited by this paper
• Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?

  2005cited by this paper
• Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma

  2005cited by this paper
• Serum Mannan-Binding Lectin-Associated Serine Protease 2 Levels in Colorectal Cancer: Relation to Recurrence and Mortality

  2005cited by this paper
• Immunosuppressive networks in the tumour environment and their therapeutic relevance

  2005cited by this paper

• The contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia and acute myelogenous leukemia

  2026cites this paper
• High burden of variants of uncertain significance in early-onset colorectal cancer among indigenous African patients: a call for global research equity in cancer genetics

  2025cites this paper
• The complement system and kidney cancer: pathogenesis to clinical applications

  2025cites this paper
• C5aR1 Promotes Invasion, Metastasis, and Poor Prognosis in Cutaneous Squamous Cell Carcinoma

  2025cites this paper
• Spatially distinct cellular and molecular landscapes define prognosis in triple-negative breast cancer.

  2025cites this paper
• A549 tumorigenic and BEAS-2B non-tumorigenic cell line derived small extracellular vesicles show distinct proteomic, N-glycoproteomic and chondroitin/dermatan sulfate profiles

  2025cites this paper
• Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma

  2025cites this paper
• Identification of Critical Genes Associated with Intrahepatic Cholangiocarcinoma: Weighted Gene Co-expression Network Analysis

  2025cites this paper
• Three-dimensional genome architecture in intrahepatic cholangiocarcinoma

  2025cites this paper
• The role of the tumor microenvironment in HNSCC resistance and targeted therapy

  2025cites this paper
• Understanding the role of C5a/C5aR1-mediated complement activation pathway in tumor progression and therapy resistance.

  2025cites this paper
• A novel ferroptosis-related signature for predicting prognosis, immune characteristics, and treatment prediction in hepatocellular carcinoma

  2025cites this paper
• Spatially distinct cellular and molecular landscapes define prognosis in triple negative breast cancer

  2025cites this paper
• Insights and perspectives into the discovery of complement-related biomarkers in cancer.

  2025cites this paper
• The role of the C5a-C5aR pathway in iron metabolism and gastric cancer progression

  2025cites this paper
• Cancerous time estimation for interpreting the evolution of lung adenocarcinoma

  2024cites this paper
• The Role of Anesthetic Management in Lung Cancer Recurrence and Metastasis: A Comprehensive Review

  2024cites this paper
• Reconstructed colorectal cancer model to dissect the anti-tumor effect of mesenchymal stromal cells derived extracellular vesicles

  2024cites this paper
• Blood hypercoagulability and thrombosis mechanisms in cancer patients -A brief review

  2024cites this paper
• Elevated expression of complement factor I in lung cancer cells associates with shorter survival - potentially via non-canonical mechanism.

  2024cites this paper
• Proteomic Analysis of Biomarkers Predicting Treatment Response in Patients with Head and Neck Cancers

  2024cites this paper
• Expression of C5aR1 in Cutaneous Squamous Cell Carcinoma is Associated with Invasion, Metastasis and Poor Prognosis

  2024cites this paper
• The complement system in clinical oncology: Applications, limitations and challenges.

  2024cites this paper
• Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors

  2024cites this paper
• Complement C3d enables protective immunity capable of distinguishing spontaneously transformed from non-transformed cells

  2024cites this paper
• Complement C3d enables cell-mediated immunity capable of distinguishing spontaneously transformed from nontransformed cells

  2024cites this paper
• Integrated glycoproteomic characterization of clear cell renal cell carcinoma.

  2023cites this paper
• The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics.

  2023cites this paper
• Human papillomavirus-mediated expression of complement regulatory proteins in human cervical cancer cells.

  2023cites this paper
• Biomarkers of lung cancer for screening and in never-smokers—a narrative review

  2023cites this paper
• Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging

  2023cites this paper
• Histopathology-assisted proteogenomics provides foundations for stratification of melanoma metastases

  2023cites this paper
• Prognostic Model and Tumor Immune Microenvironment Analysis of Complement-Related Genes in Gastric Cancer

  2023cites this paper
• Inhibition of the Complement Pathway is Implicated in the Induction of Cellular Proliferation and Migration in Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• Identification and Analysis of Crucial Genes in H. pylori-Associated Gastric Cancer Using an Integrated Bioinformatics Approach

  2023cites this paper
• Nanoparticle personalized biomolecular corona: implications of pre-existing conditions for immunomodulation and cancer.

  2022cites this paper
• Inside-Out of Complement in Cancer

  2022cites this paper
• Hypoxia-inducible lentiviral gene expression in engineered human macrophages

  2022cites this paper
• A Weakly Supervised Deep Learning Method for Guiding Ovarian Cancer Treatment and Identifying an Effective Biomarker

  2022cites this paper
• Pepsinogen/Proton Pump Co‐Expression in Barrett's Esophageal Cells Induces Cancer‐Associated Changes

  2022cites this paper
• Complement activation in cancer: Effects on tumor-associated myeloid cells and immunosuppression.

  2022cites this paper
• Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment

  2022influential citation
• Comparative Analysis of Proteomes and Phosphoproteomes in Patients with Prostate Cancer Using Different Surgical Conditions

  2022cites this paper
• The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells.

  2022cites this paper
• Nonstructural Protein 1 of Variant PEDV Plays a Key Role in Escaping Replication Restriction by Complement C3

  2022cites this paper
• Complement System: An Immunotherapy Target in Colorectal Cancer

  2022cites this paper
• Transcriptome profile and its partly verification of human hepatocellular carcinoma cells exposed to Yuzhizi () seed extract.

  2022cites this paper
• Contrast subgraphs allow comparing homogeneous and heterogeneous networks derived from omics data

  2022cites this paper
• Complement in Tumourigenesis and the Response to Cancer Therapy

  2021cites this paper
• A model based on the quantification of complement C4c, CYFRA 21–1 and CRP exhibits high specificity for the early diagnosis of lung cancer

  2021cites this paper
• The dual role of complement in cancers, from destroying tumors to promoting tumor development.

  2021cites this paper
• The screening of immune-related biomarkers for prognosis of lung adenocarcinoma

  2021cites this paper
• Integrative Analysis of Complement System to Prognosis and Immune Infiltrating in Colon Cancer and Gastric Cancer

  2021cites this paper
• A method for subtype analysis with somatic mutations

  2021cites this paper
• Inhibitory effects of circulating natural autoantibodies to CD47-derived peptides on OSCC cells.

  2021cites this paper
• Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment

  2021cites this paper
• Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics

  2021cites this paper
• C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models

  2021cites this paper
• Nanoliposomes as drug delivery systems: safety concerns

  2021cites this paper
• “Complimenting the Complement”: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma

  2021cites this paper
• The role of complement in the tumor microenvironment

  2021cites this paper
• Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer

  2021cites this paper
• A review on association of fungi with the development and progression of carcinogenesis in the human body

  2021cites this paper
• The Complement System in Ovarian Cancer: An Underexplored Old Path

  2021cites this paper
• New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene

  2021cites this paper
• Role of Complement in Regulating Inflammation Processes in Renal and Prostate Cancers

  2021cites this paper
• The Role of Alpha 2 Macroglobulin in IgG-Aggregation and Chronic Activation of the Complement System in Patients With Chronic Lymphocytic Leukemia

  2021influential citation
• Identification of Key Genes and Pathways in Gefitinib-Resistant Lung Adenocarcinoma using Bioinformatics Analysis

  2021cites this paper
• Association between ankyrin 2 gene and breast cancer progression: A preliminary computational assessment using the database approach

  2021cites this paper
• Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out

  2021cites this paper
• C5aR1 is a master regulator in Colorectal Tumorigenesis via Immune modulation

  2020cites this paper
• DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration

  2020cites this paper
• Complement Component 3 (C3) Concentrations in Cancer Patients: A Systematic Review and Meta-Analysis

  2020cites this paper
• Components of the Lectin Pathway of Complement in Haematologic Malignancies

  2020cites this paper
• Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities.

  2020cites this paper
• Plasma protein expression differs between colorectal cancer patients depending on primary tumor location

  2020cites this paper
• Inhibitory Effects of Circulating Natural Autoantibodies to CD47-derived Peptides on Oral Squamous Cell Carcinoma Cells

  2020cites this paper
• Complement sC5b-9 and CH50 increase the risk of cancer-related mortality in patients with non-small cell lung cancer

  2020cites this paper
• Proteomic profiling and identification of significant markers from high-grade osteosarcoma after cryotherapy and irradiation

  2020cites this paper
• Down-Regulation of C3aR/C5aR Inhibits Cell Proliferation and EMT in Hepatocellular Carcinoma

  2020cites this paper
• The Genes—Candidates for Prognostic Markers of Metastasis by Expression Level in Clear Cell Renal Cell Cancer

  2020cites this paper
• Identification of Novel Prognosis and Prediction Markers in Advanced Prostate Cancer Tissues Based on Quantitative Proteomics

  2020cites this paper
• Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression

  2020cites this paper
• Complement membrane attack and tumorigenesis : a systems biology approach

  2020cites this paper
• Complement System: Promoter or Suppressor of Cancer Progression?

  2020cites this paper
• C3, C3AR1, HLA-DRA, and HLA-E as potential prognostic biomarkers for renal clear cell carcinoma

  2020cites this paper
• A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma

  2020cites this paper
• Cloaking Silica Nanoparticles with Functional Protein Coatings for Reduced Complement Activation and Cellular Uptake.

  2020cites this paper
• Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions

  2020cites this paper
• DDX5 targets tissue-specific RNAs to promote intestine tumorigenesis

  2020cites this paper
• Globular C1q Receptor (gC1qR/p32/HABP1) Suppresses the Tumor-Inhibiting Role of C1q and Promotes Tumor Proliferation in 1q21-Amplified Multiple Myeloma

  2020cites this paper
• Identification of a 7-mRNA signature as a prognostic biomarker in pediatric osteosarcoma

  2020cites this paper
• Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development

  2020cites this paper
• CD46 and Oncologic Interactions: Friendly Fire against Cancer

  2020cites this paper
• Autoantibodies specific for C1q, C3b, β2-glycoprotein 1 and annexins may amplify complement activity and reduce apoptosis-mediated immune suppression.

  2020cites this paper
• Secretome analysis reveals upregulated granzyme B in human androgen-repressed prostate cancer cells with mesenchymal and invasive phenotype

  2020cites this paper
• DDX5 promotes oncogene C3 and FABP1 expressions and drives intestinal inflammation and tumorigenesis

  2020cites this paper
• Complement System in Cutaneous Squamous Cell Carcinoma

  2019cites this paper
• Microsoft Word-Tollis_humpback_manuscript_MBE_FINAL_AdvAccess.docx

  2019cites this paper
• Early diagnosis of colorectal cancer via plasma proteomic analysis of CRC and advanced adenomatous polyp

  2019cites this paper